Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 12—December 2010

Letter

Ribavirin for Lassa Fever Postexposure Prophylaxis

Christiane M. Hadi, Augustine Goba, Sheik Humarr Khan, James Bangura, Mbalu Sankoh, Saffa Koroma, Baindu Juana, Alpha Bah, Mamadou Coulibaly, and Daniel G. BauschComments to Author 
Author affiliations: Author affiliations: Tulane University Health Sciences Center, New Orleans, Louisiana, USA (C.M. Hadi, D.G. Bausch); Ministry of Health and Sanitation, Kenema, Sierra Leone (A. Goba, S.H. Khan, J. Bangura, M. Sankoh, S. Koroma, B. Juana); International Center for Research on Tropical Infections, N’Zérékoré, Guinea (A. Bah, M. Coulibaly); Tulane School of Public Health and Tropical Medicine, New Orleans (D.G. Bausch)

Main Article

Figure

Adverse effects reported by 23 persons who took oral ribavirin prophylactically after potential exposure to Lassa virus, Sierra Leone, 2004.

Figure. Adverse effects reported by 23 persons who took oral ribavirin prophylactically after potential exposure to Lassa virus, Sierra Leone, 2004.

Main Article

TOP